Outlook on the Advanced Therapy Medicinal Products CDMO Global Market to 2028 - Rising Number of Clinical Trials for ATMP is Driving Growth

News provided by

Dec 21, 2021, 14:45 ET

DUBLIN, Dec. 21, 2021 /PRNewswire/ -- The "Global Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report by Product (Gene Therapy, Cell Therapy, Tissue Engineered), Phase, Indication, Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global advanced therapy medicinal products CDMO market size is expected to reach USD 12.9 billion by 2028, according to the report. It is expected to expand at a CAGR of 12.0% from 2021 to 2028.

The advanced therapy medicinal products are a group of biological products for human use that involve gene therapy products, cell therapy products, and tissue-engineered products. The growth of the market is credited to the increasing clinical trials of ATMP and the rising awareness and belief among researchers regarding the benefits of advanced therapy. The COVID-19 pandemic has significantly disrupted the cell and gene therapy industry due to the complexity in the manufacturing process.

The COVID-19 pandemic has adversely affected the overall medical industry, but the pandemic boosted the operations and development of advanced therapy due to the high requirement of the products such as mesenchymal stromal cells (MSCs) for the treatment of the virus. The regulations put forward by the FDA and government authorities have created a safe environment for the healthcare workers and allowed emergency approval for the supply of essential raw materials and faster development of the vaccines and other therapy products.

Technological advancement has been a major part of tissue engineering in the last few years. This method helps to replace or restore the injured tissues and organ function. Similarly, gene and cell therapy is attracting many patients for the treatment of rare diseases, the cases of which are augmenting globally.

Advanced Therapy Medicinal Product CDMO Market Report Highlights

By product, the gene therapy segment held the largest revenue share in 2020 due to the rising awareness regarding the treatment and increasing number of approvals
Based on phase, the phase III segment captured the largest revenue share in 2020 as this phase ensures the safety and efficacy of the drug, leading to a large volume of drug requirement
North America led the market in 2020 and is expected to maintain its lead in the market owing to technological advancements in treatment and increasing outsourcing activities in the region. Asia Pacific is expected to witness the highest growth over the forecast period
The market has been characterized by intense competition owing to the presence of leading players

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Advanced Therapy Medicinal Products CDMO Market: Variables, Trends, & Scope
3.1 Market Segmentation and Scope
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising number of clinical trials for ATMP
3.2.1.2 Increasing outsourcing activities
3.2.1.3 Growing awareness of the treatment
3.2.2 Market Restraint Analysis
3.2.2.1 Stringent regulatory approvals
3.2.2.2 High cost of outsourcing
3.3 Penetration & Growth Prospect Mapping
3.4 Advanced Therapy Medicinal Products CDMO: Market Analysis Tools
3.4.1 Industry Analysis - Porter's
3.4.1.1 Porter's Five Forces Analysis
3.4.2 PESTEL Analysis

Chapter 4 Advanced Therapy Medicinal Products CDMO Market: Product Estimates
4.1 Market Share Analysis, 2020 & 2028
4.2 Gene Therapy
4.2.1 Gene therapy market, 2016 - 2028 (USD Billion)
4.3 Cell Therapy
4.3.1 Cell therapy market, 2016 - 2028 (USD Billion)
4.4 Tissue Engineered
4.4.1 Tissue engineered market, 2016 - 2028 (USD Billion)
4.5 Others
4.5.1 Market, 2016 - 2028 (USD Billion)

Chapter 5 Advanced Therapy Medicinal Products CDMO Market: Phase Estimates
5.1 Market Share Analysis, 2020 & 2028
5.2 Phase I
5.2.1 Phase I market, 2016 - 2028 (USD Billion)
5.3 Phase II
5.3.1 Phase II market, 2016 - 2028 (USD Billion)
5.4 Phase III
5.4.1 Phase III market, 2016 - 2028 (USD Billion)
5.5 Phase IV
5.5.1 Phase IV market, 2016 - 2028 (USD Billion)

Chapter 6 Advanced Therapy Medicinal Products CDMO Market: Indication Estimates
6.1 Market Share Analysis, 2020 & 2028
6.2 Oncology
6.2.1 Oncology market, 2016 - 2028 (USD Billion)
6.3 Cardiology
6.3.1 Cardiology market, 2016 - 2028 (USD Billion)
6.4 Central Nervous System
6.4.1 Central nervous system market, 2016 - 2028 (USD Billion)
6.5 Musculoskeletal
6.5.1 Musculoskeletal market, 2016 - 2028 (USD Billion)
6.6 Infectious Disease
6.6.1 Infectious disease market, 2016 - 2028 (USD Billion)
6.7 Dermatology
6.7.1 Dermatology market, 2016 - 2028 (USD Billion)
6.8 Endocrine, Metabolic, Genetic
6.8.1 Endocrine, metabolic, genetic market, 2016 - 2028 (USD Billion)
6.9 Immunology & inflammation
6.9.1 Immunology & inflammation market, 2016 - 2028 (USD Billion)
6.10 Ophthalmology
6.10.1 Ophthalmology market, 2016 - 2028 (USD Billion)
6.11 Haematology
6.11.1 Haematology market, 2016 - 2028 (USD Billion)
6.12 Gastroenterology
6.12.1 Gastroenterology market, 2016 - 2028 (USD Billion)
6.13 Others
6.13.1 Others market, 2016 - 2028 (USD Billion)

Chapter 7 Advanced Therapy Medicinal Products CDMO Market: Regional Analysis

Chapter 8 Company Profiles
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 Celonic
8.2.1.1 Company Overview
8.2.1.2 Financial performance
8.2.1.3 Product Benchmarking
8.2.1.5 Strategic Initiatives
8.2.2 Bio Elpida
8.2.2.1 Company Overview
8.2.2.2 Financial performance
8.2.2.3 Product Benchmarking
8.2.2.6 Strategic Initiatives
8.2.3 CGT Catapult
8.2.3.1 Company Overview
8.2.3.2 Financial performance
8.2.3.3 Product Benchmarking
8.2.3.6 Strategic Initiatives
8.2.4 Rentschler Biopharma SE
8.2.4.1 Company Overview
8.2.4.2 Financial performance
8.2.4.3 Product Benchmarking
8.2.4.6 Strategic Initiatives
8.2.5 AGC Biologics
8.2.5.1 Company Overview
8.2.5.2 Financial performance
8.2.5.3 Product Benchmarking
8.2.5.6 Strategic Initiatives
8.2.6 Catalent
8.2.6.1 Company Overview
8.2.6.2 Financial performance
8.2.6.3 Product Benchmarking
8.2.6.6 Strategic Initiatives
8.2.7 Lonza
8.2.7.1 Company Overview
8.2.7.2 Financial Performance
8.2.7.3 Product Benchmarking
8.2.7.5 Strategic Initiatives
8.2.8 WuXi Advanced Therapies
8.2.8.1 Company Overview
8.2.8.2 Financial performance
8.2.8.3 Product Benchmarking
8.2.8.5 Strategic Initiatives
8.2.9 BlueReg
8.2.9.1 Company Overview
8.2.9.2 Financial performance
8.2.9.3 Product Benchmarking
8.2.9.6 Strategic Initiatives
8.2.10 Minaris Regenerative Medicine
8.2.10.1 Company Overview
8.2.10.2 Financial performance
8.2.10.3 Product Benchmarking
8.2.10.5 Strategic Initiatives
8.2.11 Patheon
8.2.11.1 Company Overview
8.2.11.2 Financial performance
8.2.11.3 Product Benchmarking
8.2.11.5 Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/rjc62f

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets